



**UNICHEM**  
LABORATORIES LTD.

July 27, 2019

Department of Corporate Services  
Bombay Stock Exchange Ltd.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

Mr. Hari K  
Asst. Vice President - Operations  
National Stock Exchange of India Ltd  
Exchange Plaza, Bandra – Kurla Complex  
Bandra (East), Mumbai – 400 051

Dear Sir,

**Ref: BSE Scrip Code -506690: NSE Symbol – UNICHEMLAB .**

**Sub: Outcome of Board Meeting**

We would like to inform you that Board of Directors at its Meeting held today, i.e. Saturday, July 27, 2019 *interalia* approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2019. Enclosed herewith please find the Unaudited financial Results (Standalone and Consolidated) for the quarter ended June 30, 2019 and the Limited Review of the Auditors thereon.

The Board meeting commenced at 11.45 am and concluded at 1:30 pm

Kindly take the same on your records.

Thanking you,  
**FOR UNICHEM LABORATORIES LIMITED**

Neema Thakore  
Head- Legal & Company Secretary  
Encl: a/a



**Limited Review Report on quarterly standalone financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To  
The Board of Directors  
Unichem Laboratories Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Unichem Laboratories Limited ("the Company") for the quarter ended 30<sup>th</sup> June, 2019, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

**Management's responsibility for the Statement**

2. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors.

The Statement includes unaudited results for the quarter ended 31st March, 2019 being the derived figures between the audited annual figures in respect of the financial year ended 31st March, 2019 and the published unaudited figures for the nine-months ended 31st December, 2018, which were subjected to a limited review.

**Auditor's responsibility**

3. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

**Conclusion**

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards i.e. 'Ind AS' prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Limited Review Report on quarterly standalone financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (continued...)**


**5. Emphasis of matter**

We draw attention to note 9 of notes to the standalone financial results for the quarter ended 30<sup>th</sup> June 2019, which informs that the General Court of the European Union has on 12<sup>th</sup> December 2018 rejected the appeal and confirmed the fine of Euro 13.96 Million (equivalent to Rs. 10,918.12 lakhs) imposed by the European Commission jointly and severally on the Company and its subsidiary (Niche Generics Limited, UK). The Company and its subsidiary based on legal advice and merits, have filed appeals against the decision of General Court before the Court of Justice of the European Union and outcome of the appeals are awaited. Considering the above, in view of the management, no provision for the aforesaid fine is considered necessary. This matter was reported under 'Emphasis of Matter' paragraph in our auditor's report for the standalone and consolidated financial statement for the year ended 31<sup>st</sup> March 2019. Our conclusion is not modified in respect of above matter.

**For N. A. Shah Associates LLP**

Chartered Accountants

Firm's registration number: 116560W / W100149



**Milan Mody**

Partner

Membership number: 103286

UDIN: 19103286 AAADD2528

Place: Mumbai

Date: 27 JUL 2019

**Limited Review Report on quarterly consolidated financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To  
The Board of Directors  
Unichem Laboratories Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Unichem Laboratories Limited ('the Holding Company'), comprising its subsidiaries (the Holding and its subsidiaries collectively referred to as 'the Group') and its share of the net profit / (loss) after tax and total comprehensive income / loss of its associate for the quarter ended 30th June 2019 ('the Statement'), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI circular CIR/CFD/CMD1/44/2019 dated 29<sup>th</sup> March 2019 ('the Circular').

Attention is drawn to the fact that in terms of the requirement of the Circular, consolidated unaudited figures for the corresponding quarter ended 30<sup>th</sup> June 2018 and quarter ended 31<sup>st</sup> March 2019 have been approved by the Holding Company's Board of Directors, but have not been subject to limited review. Also refer note 9 of the consolidated financial results for the quarter ended 30<sup>th</sup> June 2019.

**Management's responsibility for the Statement**

2. The Statement is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors.

The Statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India.

**Auditor's responsibility**

3. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable



**Limited Review Report on quarterly consolidated financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (continued...)**

4. These consolidated financial results:

(a) includes results of the following subsidiaries:

- i. Niche Generics Limited, United Kingdom
- ii. Unichem Pharmaceuticals (USA), Inc., USA
- iii. Unichem Laboratories Limited, Ireland
- iv. Unichem SA (Pty) Limited, South Africa
- v. Unichem Farmaceutica Do Brasil Ltda, Brazil
- vi. Younikaimo Pharmaceutical (Shanghai) Pvt. Ltd., China [Unichem (China) Pvt. Ltd.] incorporated on 27<sup>th</sup> Jun, 2019.

(b) includes results of the associate: Synchron Research Services Pvt. Ltd.

**Emphasis of matter**

5. We draw attention to note 9 of notes to the consolidated financial results for the quarter ended 30<sup>th</sup> June 2019, which informs that the General Court of the European Union has on 12<sup>th</sup> December 2018 rejected the appeal and confirmed the fine of Euro 13.96 Million (equivalent to Rs.10,918.12 lakhs) imposed by the European Commission jointly and severally on the Company and its subsidiary (Niche Generics Limited, UK). The Holding Company and its subsidiary based on legal advice and merits, have filed appeals against the decision of General Court before the Court of Justice of the European Union and outcome of the appeals are awaited. This matter was reported under 'Emphasis of Matter' paragraph in auditor's report for the standalone and consolidated financial statement for the year ended 31<sup>st</sup> March 2019. Our conclusion on the Statement is not modified in respect of above matter.

**Other Matters**

6. We did not review the interim financial statements of five subsidiaries, whose financial statements reflect, total revenues (including other income) of Rs 20,432.20 lakhs and total net profit after tax of Rs 346.66 lakhs and total comprehensive income of Rs.301.14 lakhs for the quarter ended 30<sup>th</sup> June 2019, as considered in the consolidated financial results, These financial results have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and our report in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) , in so far as it relates to aforesaid subsidiaries located outside India is based on the report of other auditors. Further, there are no transactions in one subsidiary [Unichem (China) Pvt. Ltd.] incorporated on 27<sup>th</sup> June,2019.



# N. A. SHAH ASSOCIATES LLP

Chartered Accountants

**Limited Review Report on quarterly consolidated financial results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (continued...)**

The consolidated unaudited financial results also include the Group's share of net loss after tax of Rs. 23.14 lakhs for the quarter ended 30th June 2019, as considered in the consolidated unaudited financial results, in respect of one associate, whose interim financial statements have not been reviewed by us. This financial information is unaudited and have been furnished to us by the Management and our conclusion on the consolidated unaudited financial results, in so far as it relates to the amounts and disclosures included in respect of the associate are solely based on the information provided by the management. According to the information and explanations given to us by the Management, this financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of above matters.


## Conclusion

7. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For N. A. Shah Associates LLP**

Chartered Accountants

Firm's registration number: 116560W / W100149



**Milan Mody**

Partner

Membership number: 103286

UDIN: 19103286AAADE9814

Place: Mumbai


Date: 27 JUL 2019



# UNICHEM LABORATORIES LTD.

Statement of Standalone Unaudited Results for the Quarter ended 30th June, 2019.				₹ Lakhs
Particulars	Quarter ended 30th Jun'19 (Unaudited)	Quarter ended 31st Mar'19 (Unaudited)	Quarter ended 30th Jun'18 (Unaudited)	For the year ended 31st Mar' 19 (Audited)
<b>CONTINUING OPERATIONS</b>				
I Revenue from operations	23,252.14	27,708.14	20,135.44	96,773.89
II Other income	2,798.35	2,255.82	1,913.59	10,154.23
<b>III Total income (I+II)</b>	<b>26,050.49</b>	<b>29,963.96</b>	<b>22,049.03</b>	<b>1,06,928.12</b>
<b>IV EXPENSES</b>				
Cost of materials consumed	10,078.92	10,405.29	11,671.89	44,317.29
Purchase of stock-in-trade	36.18	10.71	1.91	20.86
Changes in inventories of finished goods and work-in-progress	(128.76)	1,294.26	(1,490.19)	(3,053.94)
Employee benefits expense	4,886.44	4,807.09	4,212.65	17,755.75
Finance costs	4.74	41.15	1.18	61.71
Impairment loss on financial assets (refer note 4)	-	460.59	302.83	863.42
Depreciation and amortization expense	1,685.60	1,772.22	1,234.94	6,171.25
Other expenses	10,190.77	11,210.89	9,283.64	42,949.80
<b>Total expenses (IV)</b>	<b>26,753.89</b>	<b>30,002.20</b>	<b>25,218.85</b>	<b>1,09,086.14</b>
<b>V Profit/(loss) before exceptional items and tax (III- IV)</b>	<b>(703.40)</b>	<b>(38.24)</b>	<b>(3,169.82)</b>	<b>(2,158.02)</b>
VI Exceptional items	-	-	-	-
<b>VII Profit/(loss) before tax (V-VI)</b>	<b>(703.40)</b>	<b>(38.24)</b>	<b>(3,169.82)</b>	<b>(2,158.02)</b>
VIII Tax expense				
(1) Current tax	-	-	-	-
(2) Deferred tax (Refer note 6)	(749.82)	(407.52)	(1,104.56)	(2,737.77)
(3) Short / (excess) provision for tax (earlier years) [refer note 5]	-	-	-	(124.45)
<b>IX Profit/(loss) for the period from continuing Operations (VII-VIII)</b>	<b>46.42</b>	<b>369.28</b>	<b>(2,065.26)</b>	<b>704.20</b>
<b>DISCONTINUED OPERATIONS</b>				
<b>X Discontinued Operations</b>				
A. Profit/(loss) before tax from discontinued operations (refer note 8)	-	974.25	-	246.96
B. Gain on sale of identified business (net)	-	-	-	-
<b>Profit/(Loss) for the period from discontinued operations (A+B)</b>	<b>-</b>	<b>974.25</b>	<b>-</b>	<b>246.96</b>
Tax on discontinued operations	-	349.24	-	71.24
<b>X Profit/(loss) from discontinued operations (after tax)</b>	<b>-</b>	<b>625.01</b>	<b>-</b>	<b>175.72</b>
<b>XI Profit/(loss) for the period (IX+X)</b>	<b>46.42</b>	<b>994.29</b>	<b>(2,065.26)</b>	<b>879.92</b>
XII Other Comprehensive Income/(Loss)				
A. (i) Items that will not be reclassified subsequently to profit or loss	0.79	(31.64)	(42.66)	(41.41)
(ii) Income tax expense / (credit) relating to items that will not be reclassified to profit or loss	(0.25)	9.87	14.44	12.92
B. (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>Total of Other Comprehensive Income / (Loss)</b>	<b>0.54</b>	<b>(21.77)</b>	<b>(28.22)</b>	<b>(28.49)</b>
<b>XIII Total Comprehensive Income for the period (XI+XII)</b>	<b>46.96</b>	<b>972.52</b>	<b>(2,093.48)</b>	<b>851.43</b>
XIV Paid-up equity share capital (Face value of ₹ 2/- per share)	1,408.12	1,407.67	1,406.74	1,407.67
XV Other Equity (Reserves excluding revaluation reserve)				2,71,785.74

SIGNED FOR IDENTIFICATION BY  
  
 N. A. SHAH ASSOCIATES LLP  
 MUMBAI






# UNICHEM LABORATORIES LTD.


<b>XVI</b>	Earnings per equity share (for continuing operation) in ₹:				
	(1) Basic	0.07	0.52	(2.94)	1.00
	(2) Diluted	0.07	0.52	(2.94)	1.00
<b>XVII</b>	Earnings per equity share (for discontinued operation) in ₹:				
	(1) Basic	-	0.89	-	0.25
	(2) Diluted	-	0.89	-	0.25
<b>XVIII</b>	Earnings per equity share (for discontinued & continuing operation) in ₹:				
	(1) Basic	0.07	1.41	(2.94)	1.25
	(2) Diluted	0.07	1.41	(2.94)	1.25

### Notes :

- The unaudited standalone financial results for the quarter ended 30th June, 2019 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 27th July, 2019. The statutory auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June, 2019.
- The above unaudited standalone financial results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. During the quarter, the Company has adopted Ind AS 116-Leases effective from 1st April, 2019 and this did not have any material impact on the financial results of the Company.
- Operating Segment : The Company has a single reportable segment i.e. 'Pharmaceuticals'.
- Impairment loss on financial assets in standalone financial results include provision for impairment of long-term investments in its subsidiary "Unichem Farmaceutica Do Brazil Ltda" of ₹ Nil for the quarter ended 30th June 2019 (₹ Nil for the quarter ended 31st March 2019, ₹ 302.83 lakhs for the quarter ended 30th June 2018 and ₹ 302.83 lakhs for year ended 31st March, 2019).
- Short / excess provision for income tax (net) of earlier years is on account of final tax liability as per returns filed and assessments completed.
- Deferred tax assets is recognised on tax loss (which includes weighted deduction in respect of R&D expenditure and excludes exempt income), unabsorbed tax depreciation and other temporary differences which will be offset against deferred tax liability.
- The Company's wholly owned subsidiary at China namely, "Younikaimo Pharmaceutical (Shanghai) Pvt. Ltd." [Unichem (China) Pvt. Ltd.] received a business license for operations on 27th June, 2019. This Subsidiary will cater to the sale in China, of Formulations and Active Pharmaceutical Ingredients manufactured by the Company and will also enable efficient sourcing and supply of materials from China.
- Profit in discontinued operations (Domestic formulation in India and Nepal) for the quarter ended 31st March, 2019 mainly includes reversal of provision for doubtful debts of ₹ 521.83 lakhs and other writebacks.
- The General Court of the European Union had on 12th December 2018 rejected the appeal and confirmed the fine of Euro 13.96 Million (equivalent to ₹ 10,918.12 lakhs) imposed by the European Commission jointly and severally on the Company and its subsidiary (Niche Generics Limited, UK). The Company and its subsidiary based on legal advice and merits have filed appeals against the decision of General Court before the Court of Justice of the European Union and outcome of the appeals are awaited. In the view of the Management no provision for the aforesaid fine is considered necessary. The statutory auditors have given Emphasis of Matter in their limited review report on standalone financial results for the quarter ended 30th June 2019.
- The aggregate amount of revenue expenditure incurred on Research and Development as included in the relevant expense heads is as tabulated below:


Particulars	₹ Lakhs			
	Quarter ended 30th Jun'19	Quarter ended 31st Mar'19	Quarter ended 30th Jun'18	For the year ended 31st Mar' 19
Total R&D expenditure	3,987.10	3,524.99	3,606.17	15,905.26

Place: Mumbai  
Date: 27th July, 2019



By Order of the Board  
For Unichem Laboratories Limited

**Dr. Prakash A. Mody**  
Chairman & Managing Director  
DIN No.: 00001285





# UNICHEM LABORATORIES LTD.

## Statement of Consolidated Unaudited Results for the Quarter ended 30th June, 2019.

₹ Lakhs

Particulars	Quarter ended 30th Jun'19 (Unaudited)	Quarter ended 31st Mar'19 (Unaudited) (Refer note 9)	Quarter ended 30th Jun'18 (Unaudited) (Refer note 9)	For the year ended 31st Mar' 19 (Audited)
<b>CONTINUING OPERATIONS</b>				
I Revenue from operations	29,773.52	37,424.26	24,117.03	1,18,004.68
II Other income	2,626.23	2,071.38	1,877.35	9,841.29
III <b>Total income (I+II)</b>	<b>32,399.75</b>	<b>39,495.64</b>	<b>25,994.38</b>	<b>1,27,845.97</b>
<b>IV EXPENSES</b>				
Cost of materials consumed	10,787.91	11,573.25	13,446.61	47,691.79
Purchase of stock-in-trade	36.18	10.71	1.91	20.86
Changes in inventories of finished goods and work-in-progress	(593.70)	(510.71)	(3,117.94)	(3,247.73)
Employee benefits expense	6,465.74	6,711.03	5,625.26	23,932.04
Finance costs	128.04	283.85	125.54	752.23
Impairment loss on financial assets	-	460.59	-	560.59
Depreciation and amortization expense	1,825.26	1,850.80	1,385.81	6,736.68
Other expenses	15,099.02	16,835.55	11,614.21	57,396.56
<b>Total expenses (IV)</b>	<b>33,748.45</b>	<b>37,215.07</b>	<b>29,081.40</b>	<b>1,33,843.02</b>
V Share of profit/(loss) in associate (net of tax)	(23.14)	(7.70)	28.39	6.52
VI <b>Profit/(loss) before exceptional items and tax (III- IV+V)</b>	<b>(1,371.84)</b>	<b>2,272.87</b>	<b>(3,058.63)</b>	<b>(5,990.53)</b>
VII Exceptional items	-	-	-	-
VIII <b>Profit/(loss) before tax (VI-VII)</b>	<b>(1,371.84)</b>	<b>2,272.87</b>	<b>(3,058.63)</b>	<b>(5,990.53)</b>
<b>IX Tax expense</b>				
(1) Current tax	194.77	713.81	91.65	713.83
(2) Deferred tax (Refer note 5)	(947.79)	(1,615.06)	(1,104.56)	(4,024.15)
(3) Short / (excess) provision for tax (earlier years) (Refer note 4)	-	-	-	(124.45)
X <b>Profit/(loss) for the period from continuing Operations (VIII- IX)</b>	<b>(618.82)</b>	<b>3,174.12</b>	<b>(2,045.72)</b>	<b>(2,555.76)</b>
<b>DISCONTINUED OPERATIONS</b>				
<b>XI Discontinued Operations</b>				
A. Profit/(loss) before tax from discontinued operations (refer note 7)	-	974.25	-	246.96
B. Gain on sale of identified business (net)	-	-	-	-
<b>Profit/(Loss) for the period from discontinued operations (A+B)</b>	<b>-</b>	<b>974.25</b>	<b>-</b>	<b>246.96</b>
Tax on discontinued operations	-	349.24	-	71.24
<b>Profit/(loss) from discontinued operations (after tax)</b>	<b>-</b>	<b>625.01</b>	<b>-</b>	<b>175.72</b>
XII <b>Profit/(loss) for the period (X+XI)</b>	<b>(618.82)</b>	<b>3,799.13</b>	<b>(2,045.72)</b>	<b>(2,380.04)</b>
<b>XIII Other Comprehensive Income/(Loss)</b>				
A. (i) Items that will not be reclassified subsequently to profit or loss	0.79	(31.64)	(42.66)	(41.41)
(ii) Income tax expense / (credit) relating to items that will not be reclassified to profit or loss	(0.25)	9.87	14.44	12.92
B. (i) Items that will be reclassified to profit or loss	(136.65)	(104.53)	130.69	215.46
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>Total of Other Comprehensive Income / (Loss)</b>	<b>(136.11)</b>	<b>(126.30)</b>	<b>102.47</b>	<b>186.97</b>
XIV <b>Total Comprehensive Income for the period (XII+XIII)</b>	<b>(754.93)</b>	<b>3,672.83</b>	<b>(1,943.25)</b>	<b>(2,193.07)</b>
XV Paid-up equity share capital (Face value of ₹ 2/- per share)	1,408.12	1,407.67	1,406.74	1,407.67
XVI Other Equity (Reserves excluding revaluation reserve)				2,60,583.02

SIGNED FOR IDENTIFICATION BY  
*A. V. Kholy*  
N. A. SHAH ASSOCIATES LLP  
MUMBAI



Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road, Jogeshwari (West), Mumbai – 400 102, Maharashtra, India.

Tel.: +91 (22) 66888333 • Fax.: +91 (22) 26784391 • Website: www.unichemlabs.com • CIN: L99999MH1962PLC012451 Page 1 of 2



# UNICHEM LABORATORIES LTD.

<b>XVII</b>	Earnings per equity share (for continuing operation) in ₹:				
	(1) Basic	(0.88)	4.51	(2.91)	(3.63)
	(2) Diluted	(0.88)	4.51	(2.91)	(3.63)
<b>XVIII</b>	Earnings per equity share (for discontinued operation) in ₹ :				
	(1) Basic	-	0.89	-	0.25
	(2) Diluted	-	0.89	-	0.25
<b>XIX</b>	Earnings per equity share (for discontinued & continuing operation) in ₹:				
	(1) Basic	(0.88)	5.40	(2.91)	(3.38)
	(2) Diluted	(0.88)	5.40	(2.91)	(3.38)

#### Notes :

- The unaudited consolidated financial results for the quarter ended 30th June, 2019 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 27th July, 2019. The statutory auditors have carried out a limited review of the consolidated financial results for the quarter ended 30th June, 2019.
- The above unaudited consolidated financial results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. During the quarter, the Company has adopted Ind AS 116-Leases effective from 1st April, 2019 and this did not have any material impact on the financial results of the Company.
- Operating Segment : The Company has a single reportable segment i.e. 'Pharmaceuticals'.
- Short / excess provision for income tax (net) of earlier years is on account of final tax liability as per returns filed and assessments completed.
- Deferred tax assets is recognised on tax loss (which includes weighted deduction in respect of R&D expenditure and excludes exempt income), unabsorbed tax depreciation and other temporary differences which will be offset against deferred tax liability.
- The Company's wholly owned subsidiary at China namely, "Younikaimo Pharmaceutical (Shanghai) Pvt. Ltd." [Unichem (China) Pvt. Ltd.] received a business license for operations on 27th June, 2019. This Subsidiary will cater to the sale in China, of Formulations and Active Pharmaceutical Ingredients manufactured by the Company and will also enable efficient sourcing and supply of materials from China.
- Profit in discontinued operations for the quarter ended 31st March, 2019 mainly includes reversal of provision for doubtful debts of ₹ 521.83 lakhs and other writebacks.
- The General Court of the European Union had on 12th December 2018 rejected the appeal and confirmed the fine of Euro 13.96 Million (equivalent to ₹ 10,918.12 lakhs) imposed by the European Commission jointly and severally on the Company and its subsidiary (Niche Generics Limited, UK). The Company and its subsidiary based on legal advice and merits have filed appeals against the decision of General Court before the Court of Justice of the European Union and outcome of the appeals are awaited. In the view of the Management no provision for the aforesaid fine is considered necessary. The statutory auditors have given Emphasis of Matter in their limited review report on consolidated financial results for the quarter ended 30th June 2019.
- The consolidated unaudited figures for the quarter ended 31st March 2019 are balancing figures between the audited figures in respect of the full financial year upto 31st March, 2019 and the unaudited year to date figures upto 31st December, 2018. The consolidated figures for the corresponding quarter ended 30th June 2018 and for the quarter ended 31st March, 2019 are approved by the Board of Directors and have not been subjected to Limited review by the auditors.
- The aggregate amount of revenue expenditure incurred on Research and Development as included in the relevant expense heads is as tabulated below:

Particulars	₹ Lakhs			
	Quarter ended 30th Jun'19	Quarter ended 31st Mar'19	Quarter ended 30th Jun'18	For the year ended 31st Mar' 19
Total R&D expenditure	3,987.10	3,524.99	3,606.17	15,905.26

Place: Mumbai  
Date: 27th July, 2019



By Order of the Board  
For Unichem Laboratories Limited

*Dr. Prakash A. Mody*  
Chairman & Managing Director  
DIN No.: 00001285

SIGNED FOR IDENTIFICATION BY  
*N. A. Shah*  
N. A. SHAH ASSOCIATES LLP

Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road, Jogeshwari (West), Mumbai - 400 102, Maharashtra, India.

Tel.: +91 (22) 66888333 • Fax.: +91 (22) 26784391 • Website: www.unichemlabs.com • CIN: L99999MH1962PLC012451 Page 2 of 2